Although there are good data supporting the use of chemotherapy in resectable pancreatic cancer, the role of adjuvant radiation is controversial, with past studies suggesting that it does not improve survival. New research examining recurrence patterns as an outcome measure sheds some light on why chemoradiation may not benefit patients with pancreatic ductal adenocarcinoma (PDAC).
“Pancreatic cancer patients who die usually die from distant recurrence. Radiation reduces only local